文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

利奈唑胺群体药代动力学分析综述

A Review of Population Pharmacokinetic Analyses of Linezolid.
PubMed 文献 · Clin Pharmacokinet · 2022-06-14

本文系统综述了利奈唑胺的群体药代动力学研究,共纳入32项采用参数化非线性混合效应模型的分析,涵盖成人与儿童。研究显示多数模型存在高个体间变异,肾功能损害、肝衰竭、高龄或低体重患者暴露更高且不良反应率增加,而肥胖、年轻及接受肾脏替代治疗者浓度较低且治疗失败相关。蒙特卡罗模拟提示标准剂量600 mg每12小时在目标病原体高MIC时可能导致毒性或治疗失败,治疗药物监测在相当比例患者中可能有必要。

要点

  • 肾功能损害、肝衰竭、高龄或低体重患者利奈唑胺暴露更高,不良反应风险增加。
  • 肥胖、年轻及接受肾脏替代治疗者浓度较低,与治疗失败相关。
  • 标准剂量600 mg每12小时在高MIC时可能毒性或失败,TDM在多数患者中可能必要。

核心结论

  • 利奈唑胺群体药代动力学模型普遍显示高个体间变异,特殊人群暴露差异显著,标准剂量在部分患者中可能导致毒性或治疗失败。

研究设计与样本

  • 检索PubMed和EMBASE数据库,纳入采用参数化非线性混合效应方法的利奈唑胺群体药代动力学分析,包括观察性和前瞻性试验,共32项研究。

主要发现

  • 32项研究中26项在成人中开展,4项在儿童中开展,1项同时纳入成人和儿童。
  • 多数模型确定高个体间变异,与既往观察性研究中利奈唑胺浓度变异一致。
  • 肾功能损害、肝衰竭、高龄或低体重患者暴露更高且不良反应率增加;肥胖、年轻及接受肾脏替代治疗者浓度较低且治疗失败相关。
  • 危重症患者个体间和个体内变异更大,提示低暴露和过暴露风险更高。
  • 蒙特卡罗模拟显示标准剂量600 mg每12小时在目标病原体高MIC时可能导致毒性或治疗失败。

关键数值与推荐

  • 标准剂量600 mg每12小时在目标病原体高MIC值时可能导致毒性或治疗失败(基于蒙特卡罗模拟)。

临床怎么用

  • 在肾功能损害、肝衰竭、高龄、低体重、肥胖、年轻、接受肾脏替代治疗及危重症患者中应关注利奈唑胺暴露差异。
  • 对相当比例患者可考虑开展治疗药物监测以优化剂量。

局限性

  • 进一步研究肾功能、肝功能及P-糖蛋白相关药物相互作用等协变量有助于解释变异并改进给药方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, many studies on population pharmacokinetics of linezolid have been conducted. This comprehensive review aimed to summarize population pharmacokinetic models of linezolid, by focusing on dosage optimization to maximize the probability of attaining a certain pharmacokinetic-pharmacodynamic parameter in special populations. We searched the PubMed and EMBASE databases for population pharmacokinetic analyses of linezolid using a parametric non-linear mixed-effect approach, including both observational and prospective trials. Of the 32 studies, 26 were performed in adults, four in children, and one in both adults and children. High between-subject variability was determined in the majority of the models, which was in line with the variability of linezolid concentrations previously detected in observational studies. Some studies found that patients with renal impairment, hepatic failure, advanced age, or low body weight had higher exposure and adverse reactions rates. In contrast, lower concentrations and therapeutic failure were associated with obese patients, young patients, and patients who had undergone renal replacement techniques. In critically ill patients, the inter-individual and intra-individual variability was even greater, suggesting that this population is at an even higher risk of underexposure and overexposure. Therapeutic drug monitoring may be warranted in a large proportion of patients given that the Monte Carlo simulations demonstrated that the one-size-fits-all labeled dosing of 600 mg every 12 h could lead to toxicity or therapeutic failure for high values of the minimum inhibitory concentration of the target pathogen. Further research on covariates, including renal function, hepatic function, and drug-drug interactions related to P-glycoprotein could help to explain variability and improve linezolid dosing regimens.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, et al. A Review of Population Pharmacokinetic Analyses of Linezolid. Clin Pharmacokinet. 2022. PMID: 35699914. doi:10.1007/s40262-022-01125-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。